416 related articles for article (PubMed ID: 2479178)
21. Early treatment trials with interferon beta in multiple sclerosis.
Panitch HS
Mult Scler; 1995; 1 Suppl 1():S17-21. PubMed ID: 9345392
[TBL] [Abstract][Full Text] [Related]
22. Interferons in oncology.
Woll PJ; Pettengell R
Br J Clin Pract; 1997 Mar; 51(2):111-5. PubMed ID: 9158255
[TBL] [Abstract][Full Text] [Related]
23. Biological response modifiers in cancer therapy.
Gupta S; Kanodia AK
Natl Med J India; 2002; 15(4):202-7. PubMed ID: 12296474
[TBL] [Abstract][Full Text] [Related]
24. Interferons in the treatment of malignancies.
Kardamakis D
In Vivo; 1991; 5(6):589-97. PubMed ID: 1810444
[TBL] [Abstract][Full Text] [Related]
25. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
26. [Update on the use of interferons in clinical practice].
Lauta VM
Clin Ter; 1995; 146(6-7):393-448. PubMed ID: 7586995
[TBL] [Abstract][Full Text] [Related]
27. Interferons as potential adjuvants in prophylactic vaccines.
Toporovski R; Morrow MP; Weiner DB
Expert Opin Biol Ther; 2010 Oct; 10(10):1489-500. PubMed ID: 20836750
[TBL] [Abstract][Full Text] [Related]
28. Biologicals and biological response modifiers: fourth modality of cancer treatment.
Oldham RK
Cancer Treat Rep; 1984 Jan; 68(1):221-32. PubMed ID: 6198081
[TBL] [Abstract][Full Text] [Related]
29. [Interferons. Treatment of malignant hemopathies with interferons].
Guilhot F; Sadoun A; Delwail V
Ann Med Interne (Paris); 1993; 144(8):548-56. PubMed ID: 7513980
[TBL] [Abstract][Full Text] [Related]
30. [Possibilities and limits of the use of interferons in the clinic].
Ludwig CU
Schweiz Med Wochenschr; 1989 Nov; 119(44):1539-43. PubMed ID: 2479977
[TBL] [Abstract][Full Text] [Related]
31. [Interferons].
Pape GR
Schweiz Rundsch Med Prax; 1992 Sep; 81(36):1039-40. PubMed ID: 1384099
[TBL] [Abstract][Full Text] [Related]
32. [Interferons in the treatment of solid tumors. A general review].
Dorval T; Pouillart P
Bull Cancer; 1988; 75(9):885-8. PubMed ID: 2462946
[TBL] [Abstract][Full Text] [Related]
33. Interferons: biological and clinical effects.
Nelson BE; Borden EC
Semin Surg Oncol; 1989; 5(6):391-401. PubMed ID: 2480628
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic role of beta-interferons in multiple sclerosis.
Javed A; Reder AT
Pharmacol Ther; 2006 Apr; 110(1):35-56. PubMed ID: 16229894
[TBL] [Abstract][Full Text] [Related]
35. Biological effects of interferons and their role in onco-hematological conditions.
Agostini C; Pizzolo G; Semenzato G
Allergol Immunopathol (Madr); 1991; 19(5):187-93. PubMed ID: 1725840
[No Abstract] [Full Text] [Related]
36. [Human interferons: biological and clinical promises and premises].
Jasmin C
Schweiz Med Wochenschr; 1991 Mar; 121(13):463-6. PubMed ID: 1709521
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic use of alpha interferon in metastasizing malignant melanoma, disseminated Kaposi sarcoma and severe Behçet disease].
Stadler R; Bratzke B; Orfanos CE
Hautarzt; 1987 Aug; 38(8):453-60. PubMed ID: 3654216
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
Garbe C
Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
[TBL] [Abstract][Full Text] [Related]
39. [Immunotherapy of cancer today and first trials of "modifiers of host-tumor relations"].
Mathé G
Rev Prat; 1981 Oct; 31(43):3057-60 passim. PubMed ID: 6170108
[No Abstract] [Full Text] [Related]
40. Type I interferons as vaccine adjuvants against infectious diseases and cancer.
Bracci L; La Sorsa V; Belardelli F; Proietti E
Expert Rev Vaccines; 2008 Apr; 7(3):373-81. PubMed ID: 18393607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
